Literature DB >> 16957773

Secretion of L-glutamate from osteoclasts through transcytosis.

Riyo Morimoto1, Shunsuke Uehara, Shouki Yatsushiro, Narinobu Juge, Zhaolin Hua, Shigenori Senoh, Noriko Echigo, Mitsuko Hayashi, Toshihide Mizoguchi, Tadashi Ninomiya, Nobuyuki Udagawa, Hiroshi Omote, Akitsugu Yamamoto, Robert H Edwards, Yoshinori Moriyama.   

Abstract

Osteoclasts are involved in the catabolism of the bone matrix and eliminate the resulting degradation products through transcytosis, but the molecular mechanism and regulation of transcytosis remain poorly understood. Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of glutamate in neurons. VGLUT1 is localized in transcytotic vesicles and accumulates L-glutamate. Osteoclasts secrete L-glutamate and the bone degradation products upon stimulation with KCl or ATP in a Ca2+-dependent manner. KCl- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from VGLUT1-/- knockout mice. Osteoclasts express mGluR8, a class III metabotropic glutamate receptor. Its stimulation by a specific agonist inhibits secretion of L-glutamate and bone degradation products, whereas its suppression by a specific antagonist stimulates bone resorption. Finally, it was found that VGLUT1-/- mice develop osteoporosis. Thus, in bone-resorbing osteoclasts, L-glutamate and bone degradation products are secreted through transcytosis and the released L-glutamate is involved in autoregulation of transcytosis. Glutamate signaling may play an important role in the bone homeostasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957773      PMCID: PMC1570443          DOI: 10.1038/sj.emboj.7601317

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 2.  Intracellular membrane trafficking in bone resorbing osteoclasts.

Authors:  Mika Mulari; Jukka Vääräniemi; H Kalervo Väänänen
Journal:  Microsc Res Tech       Date:  2003-08-15       Impact factor: 2.769

3.  Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function.

Authors:  T Suda; E Jimi; I Nakamura; N Takahashi
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; T Sasaki; A Yamaguchi; H Kodama; T J Martin; T Suda
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  Vesicular storage and secretion of L-glutamate from glucagon-like peptide 1-secreting clonal intestinal L cells.

Authors:  Shunsuke Uehara; Sun-Kyung Jung; Riyo Morimoto; Shigeo Arioka; Takaaki Miyaji; Narinobu Juge; Miki Hiasa; Kahori Shimizu; Akinori Ishimura; Masato Otsuka; Akitsugu Yamamoto; Pierre Maechler; Yoshinori Moriyama
Journal:  J Neurochem       Date:  2005-12-08       Impact factor: 5.372

6.  Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts.

Authors:  H Palokangas; M Mulari; H K Väänänen
Journal:  J Cell Sci       Date:  1997-08       Impact factor: 5.285

Review 7.  Glutamate signalling and its potential application to tissue engineering of bone.

Authors:  Deborah J Mason
Journal:  Eur Cell Mater       Date:  2004-04-07       Impact factor: 3.942

8.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

9.  p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function.

Authors:  Xiaotong Li; Nobuyuki Udagawa; Kanami Itoh; Koji Suda; Yoshiyuki Murase; Tatsuji Nishihara; Tatsuo Suda; Naoyuki Takahashi
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

10.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more
  35 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

Review 2.  The role of osteoclast differentiation and function in skeletal homeostasis.

Authors:  Kyoji Ikeda; Sunao Takeshita
Journal:  J Biochem       Date:  2015-11-03       Impact factor: 3.387

Review 3.  Regulation of osteoclast polarization.

Authors:  Naoyuki Takahashi; Sadakazu Ejiri; Shigeru Yanagisawa; Hidehiro Ozawa
Journal:  Odontology       Date:  2007-07-25       Impact factor: 2.634

Review 4.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

5.  The dynamin inhibitor dynasore inhibits bone resorption by rapidly disrupting actin rings of osteoclasts.

Authors:  Gnanasagar J Thirukonda; Shunsuke Uehara; Takahiro Nakayama; Teruhito Yamashita; Yukio Nakamura; Toshihide Mizoguchi; Naoyuki Takahashi; Kimitoshi Yagami; Nobuyuki Udagawa; Yasuhiro Kobayashi
Journal:  J Bone Miner Metab       Date:  2015-06-11       Impact factor: 2.626

6.  Tctex-1, a novel interaction partner of Rab3D, is required for osteoclastic bone resorption.

Authors:  Nathan J Pavlos; Tak Sum Cheng; An Qin; Pei Ying Ng; Hao-Tian Feng; Estabelle S M Ang; Amerigo Carrello; Ching-Hwa Sung; Reinhard Jahn; Ming-Hao Zheng; Jiake Xu
Journal:  Mol Cell Biol       Date:  2011-01-24       Impact factor: 4.272

7.  Docetaxel inhibits bone resorption through suppression of osteoclast formation and function in different manners.

Authors:  Masahiro Takahashi; Toshihide Mizoguchi; Shunsuke Uehara; Yuko Nakamichi; Shuhua Yang; Hiroko Naramoto; Teruhito Yamashita; Yasuhiro Kobayashi; Minoru Yamaoka; Kiyofumi Furusawa; Nobuyuki Udagawa; Takashi Uematsu; Naoyuki Takahashi
Journal:  J Bone Miner Metab       Date:  2008-12-13       Impact factor: 2.626

8.  Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter.

Authors:  Eiichi Hinoi; Takeshi Takarada; Kyosuke Uno; Maki Inoue; Yasuhiro Murafuji; Yukio Yoneda
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

9.  Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis.

Authors:  HaoTian Feng; Taksum Cheng; James H Steer; David A Joyce; Nathan J Pavlos; Chengloon Leong; Jasreen Kular; Jianzhong Liu; Xu Feng; Ming H Zheng; Jiake Xu
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

10.  Osteoclast-induced Foxp3+ CD8 T-cells limit bone loss in mice.

Authors:  Zachary S Buchwald; Jennifer R Kiesel; Chang Yang; Richard DiPaolo; Deborah V Novack; Rajeev Aurora
Journal:  Bone       Date:  2013-06-10       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.